"The SOLSTICE phase 2b trial showed that the oral GLP-1 receptor agonist elecoglipron significantly lowered blood glucose and body weight. Up to 89.6% of participants achieved target HbA1c levels, and 72.3% achieved significant weight loss. The drug aims to overcome delivery constraints of current injectable GLP-1 therapies."